Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/51084
Título: Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention
Autores/as: Alemany, Laia
Pérez, Cristina
Tous, Sara
Llombart-Bosch, Antonio
Lloveras, Belen
Lerma, Enrique
Guarch, Rosa
Andújar, Miguel 
Pelayo, Adela
Alejo, Maria
Ordi, Jaume
Klaustermeier, Joellen
Velasco, Julio
Guimerà, Nuria
Clavero, Omar
Castellsagué, Xavier
Quint, Wim
Muñoz, Nubia
Bosch, F. Xavier
De Sanjosé, Silvia
Clasificación UNESCO: 32 Ciencias médicas
320713 Oncología
320108 Ginecología
241210 Vacunas
Palabras clave: Cervical cancer
HPV types
Spain
Time trends
Vaccines
Fecha de publicación: 2012
Publicación seriada: Gynecologic Oncology 
Resumen: Objective Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA25) (version 1). Results Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV 16, 18, 33, 31, 45, 35, 52 and 56, accounting for more than 90% of cases. HPV 16 and 18 contributed to 72.4% of all HPV positive ICC cases. In cervical adenocarcinomas, this contribution increased up to 94%. HPV 16 and 18 relative contributions showed a stable pattern over the 60 year study period. HPV 45, 18 and 16-positive ICC cases presented at younger ages than cases with other HPV types (adjusted mean age: 43.8, 45.2, 52.6 and 57.7 years, respectively). Conclusions HPV 16 and 18 accounted together for a 72.4% of positive cases, with no statistically significant changes in their relative contributions over the last decades. In 94% of cervical adenocarcinomas we identified at least one of the two HPV types included in the current vaccines (HPV 16/18). Results suggest a major impact of HPV vaccines on reduction of ICC burden in Spain in the HPV vaccinated cohorts.
URI: http://hdl.handle.net/10553/51084
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2011.11.024
Fuente: Gynecologic Oncology[ISSN 0090-8258],v. 124(3), p. 512-517 (Marzo 2012)
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.